Skip to content

UK to Expand CCP Virus Mass Testing

  • World

FedEx Cargo Jet Makes Predawn Emergency Landing in Los Angeles

Sparks erupted from the bottom of a FedEx cargo jet as it made a predawn emergency landing Wednesday at Los Angeles International Airport, officials said. A man who was hurt while leaving the aircraft was taken to a hospital, said airport spokeswoman Olga Gallardo. His condition was unknown, but the injury was described as not life-threatening. Only two people were on board, she said. FedEx Flight 1026, a Boeing 767, experienced a landing gear malfunction while landing about around 4:50 a.m. PDT, said Ian Gregor, a spokesman with the Federal Aviation Administration (FAA). A pilot can be heard saying on an air traffic control audio recording: “I don’t think there’s much more we can do. So probably going to start hashing plans for an approach.” The crew was unable to…

UK to Expand CCP Virus Mass Testing

Regular COVID-19 testing in England is to be expanded to 400,000 people as part of a national survey to track the spread of the CCP virus, the UK government said on Wednesday.

The government’s aim is to increase weekly data to better track asymptomatic cases and local outbreaks, helping to localize any future measures to stop the virus spread and impact fewer people.

“The data and insight gathered will help inform our national, regional, and local responses to the pandemic, allowing this nation to get back to the things we love doing,” Health Secretary Matt Hancock said in a statement.

The Office for National Statistics (ONS) COVID-19 infection survey currently tests 28,000 people per fortnight.

More people will be invited to take part in the survey, with the initial aim to increase testing to 150,000 people by October. The goal is to enrol 400,000 people in the survey, the Department of Health and Social Care said in a statement.

The ONS survey, undertaken with The University of Oxford, will be the UK’s biggest study to track the CCP (Chinese Communist Party) virus, commonly known as novel coronavirus, in the general population, and will be extended to include Scotland, Wales, and Northern Ireland.

Widespread testing is seen as one way to reopen the economy, which suffered a record 20 percent contraction in the second quarter and is expected to see unemployment soar when the government ends its huge job subsidy program in October.

UK to Expand CCP Virus Mass Testing A paramedic holds a test tube containing a blood sample during an antibody testing program in Birmingham, Britain, on June 5, 2020. (Simon Dawson/POOL/AFP/Getty Images)

According to recent ONS data, almost three-quarters of people testing positive for the virus do not report any symptoms.

Speaking to BBC Breakfast on Wednesday, Hancock said the survey would help find more cases where people are asymptomatic.

“The biggest gap, the biggest challenge we’ve got, is finding people who don’t have symptoms—so don’t know that they’ve got coronavirus, but can still pass it on—and getting tested,” he said.

“This survey will help us to pinpoint where the virus is even amongst people who don’t know they’ve got it.”

Home Visits

During home visits from trained health workers, survey participants will answer health-related questions and give samples from self-administered nose and throat swabs showing whether they have the virus.

Some will have blood tests to test for antibodies, and tests will be repeated weekly for five weeks and monthly for a year.

The government hopes the data will provide a much more detailed national picture of CCP virus prevalence, including who is affected and where.

The ONS will initially prioritize ramping up testing in North West England and London as recent studies showed a higher incidence in those areas.

UK to Expand CCP Virus Mass Testing Social distancing signs are seen in Blackburn town centre, England, on July 17, 2020, amid the CCP virus pandemic. (Christopher Furlong/Getty Images)

Hancock said the government was trialing a range of new, faster tests that can give instant results and hoped to roll them out towards the end of the year.

He said the country’s research laboratories at Porton Down were trialing new saliva tests that do not need to go to a laboratory, so they can deliver faster results.

“There are new technologies coming on track which we are buying and testing now,” he told BBC Radio 4. “We’ll ramp it up certainly over the remainder of this year.”

Symptom Study App

In addition to the survey expansion, the government announced that a 2-million-pound ($2.6 million) grant will be given to health science start-up company ZOE for its COVID-19 Symptom Study app, which the firm has thus far self-financed.

“We are a start-up, so we are delighted that this funding guarantees the future of the study throughout the winter,” Jonathan Wolf, CEO of non-profit ZOE, said in a statement.

The app is used to track COVID-19 cases, and is currently used by 4 million people as part of a study that began at the start of the UK lockdown in March.

“We have been blown away by the commitment of the British public to help fight COVID, by sharing the state of their health daily,” Wolf said.

Study volunteers use the app to report testing results and symptoms in “the largest public science project of its kind anywhere in the world,” the government said.

Anonymized data is analyzed by King’s College London researchers for the prevalence of both symptomatic and asymptomatic infection and how this varies according to geography, age, and ethnicity.

According to ZOE, “the app’s research proved that loss of smell is a major symptom of COVID,” with the research being published in the journal Nature Medicine in May.

Along with the ONS survey data, the app’s “vital new intelligence” will help inform NHS decision-making by identifying who is most at risk and where the higher risk areas are, the government said.

Reuters contributed to this report.

Focus News: UK to Expand CCP Virus Mass Testing

J&J Strikes $6.5 Billion Deal for Autoimmune Disease Specialist Momenta

Johnson & Johnson agreed to buy Momenta Pharmaceuticals Inc for about $6.5 billion on Wednesday, to bolster its portfolio of drugs for hard-to-treat autoimmune diseases. The acquisition, latest in a recent spate of healthcare deals, comes just days after France’s Sanofi struck a $3.7 billion deal to buy Principia Biopharma Inc for its pipeline of autoimmune disease treatments. Treatments targeting autoimmune conditions have fetched billions of dollars in sales, including AbbVie Inc’s Humira, which is the world’s best-selling drug. J&J’s Janssen unit will gain access to Momenta’s experimental therapy, nipocalimab, which is in late-stage testing for warm antibody hemolytic anemia, a condition that causes destruction of healthy red blood cells, and mid-stage testing for myasthenia gravis, a neuromuscular disease. Nipocalimab is expected to eventually win approval to treat several conditions,…